Entrada Therapeutics Inc. has appointed Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, having previously served as Executive Partner at Sofinnova Investments and as Chief Medical Officer at Biogen. This appointment comes as Entrada continues to advance its Duchenne muscular dystrophy programs and expands its pipeline of intracellular therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.